LivaNova (NASDAQ:LIVN) Price Target Raised to $81.00

LivaNova (NASDAQ:LIVN) had its price target increased by Needham & Company LLC from $64.00 to $81.00 in a research report released on Wednesday morning, MarketBeat.com reports. They currently have a buy rating on the stock.

Several other research analysts have also commented on the stock. Piper Sandler restated an “overweight” rating and issued a $85.00 price target on shares of LivaNova in a report on Thursday, February 19th. Wall Street Zen raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th. Stifel Nicolaus lifted their target price on shares of LivaNova from $65.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Weiss Ratings reiterated a “sell (d+)” rating on shares of LivaNova in a report on Monday, December 29th. Finally, Barclays raised their price objective on LivaNova from $58.00 to $67.00 and gave the company an “equal weight” rating in a research report on Friday, January 9th. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, LivaNova has an average rating of “Moderate Buy” and an average price target of $74.78.

LivaNova Trading Down 0.6%

Shares of LIVN opened at $70.60 on Wednesday. LivaNova has a twelve month low of $32.48 and a twelve month high of $71.92. The firm has a market capitalization of $3.86 billion, a P/E ratio of -15.83 and a beta of 0.97. The company has a current ratio of 1.36, a quick ratio of 1.12 and a debt-to-equity ratio of 0.29. The stock’s fifty day simple moving average is $64.74 and its 200 day simple moving average is $59.04.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, February 25th. The company reported $0.86 EPS for the quarter, topping the consensus estimate of $0.80 by $0.06. The company had revenue of $360.86 million during the quarter, compared to analyst estimates of $354.31 million. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.The firm’s revenue was up 12.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.81 earnings per share. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. On average, equities research analysts forecast that LivaNova will post 2.85 earnings per share for the current year.

Institutional Trading of LivaNova

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Artisan Partners Limited Partnership lifted its stake in shares of LivaNova by 94.5% in the third quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock worth $127,129,000 after acquiring an additional 1,179,436 shares in the last quarter. Wellington Management Group LLP increased its holdings in LivaNova by 83.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock worth $122,858,000 after purchasing an additional 1,067,349 shares during the last quarter. Invesco Ltd. raised its position in shares of LivaNova by 714.7% in the 2nd quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock valued at $46,313,000 after purchasing an additional 902,447 shares in the last quarter. Scopia Capital Management LP purchased a new position in shares of LivaNova during the 2nd quarter valued at approximately $36,657,000. Finally, Millennium Management LLC raised its holdings in LivaNova by 22.4% in the third quarter. Millennium Management LLC now owns 2,969,814 shares of the company’s stock valued at $155,559,000 after acquiring an additional 544,033 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.